title: Sequential therapy in plaque psoriasis using the " Hit and Run " approach: infliximab followed by efalizumab.
authors.forename: Séverine
authors.initials: S
authors.lastname: Penz
authors.forename: Fabien
authors.initials: F
authors.lastname: Pelletier
authors.forename: Marie Odile
authors.initials: MO
authors.lastname: Riou-Gotta
authors.forename: Eve
authors.initials: E
authors.lastname: Puzenat
authors.forename: Julien
authors.initials: J
authors.lastname: Levang
authors.forename: Isabelle
authors.initials: I
authors.lastname: Mermet
authors.forename: Philippe
authors.initials: P
authors.lastname: Humbert
authors.forename: François
authors.initials: F
authors.lastname: Aubin
mesh_terms: D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents / Q000008:administration & dosage*; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D000069285:Infliximab; C472181:efalizumab